March 2022: Universitas Texas MD Anderson Cancer Centrum investigatores indagatores axi-cel antigenum chimaericum antigenum (car T-cell theraphim) autologum repererunt, tutam et efficacem theraphim in prima linea patientibus magno periculo magno B-cell. lymphoma (LBCL), coetus in desperatis novis curationibus efficacibusque necessariis.
Inventiones hae praesentatae sunt in Societate Hematologiae Americanae virtualem 2020 Annuum Conventum.
Traditionaliter, circa dimidium aegrorum cum magno periculo LBCL, subgroup morborum in quo lymphoma duplicatum vel triplum hitum habent vel factores periculi clinici, qui in Prognostico Internationali Indice (IPI) notantur, diu terminus morbus non est consecutus. remissio cum norma curationi accedit ut chemoimmunotherapy.
Hoc iudicium constituit gradum faciens CAR T Lorem cellulam a first-line treatment option for patients with aggressive B-cell lymphoma,” said Sattva S. Neelapu, M.D., professor of lymphoma and Myeloma. “At the moment, patients with newly diagnosed aggressive B-cell lymphoma get chemotherapy for about six months. CAR T Lorem cellulamsi bene, unum tempus infusio curationum uno mense perfici potest.
Ex clavibus investigationis ZUMA-1, Axi-cel nunc licentiatus est pro curatione hominum relapsus vel refractorius LBCL qui iam duas vel plures lineas curationum systemicarum iam habuit. ZUMA-12 probatio est Phase 2 apertus titulus, simplex bracchium, multicenter iudicium quod super inventiones ZUMA-1 aedificat, ad usum axi-cel perpendendi sicut primi lineae therapiae pro aegris magno periculo LBCL .
Secundum ZUMA-12 interim studium, 85 centesimas aegrorum cum axi-cel tractatas altiore responsione habuit, et 74% plenam responsionem habuit. Post mediana sectarum 9.3 mensium, 70% aegrorum conscriptorum responsionem continuam in notitia intervalli exhibebat.
Album sanguinis cellam computant reductionem, encephalopathy, anaemia, et cytokine release syndrome maxime communes effectus cum axi-cel curatione coniunctum erant. Per tempus notitia resolvitur, omnia adversis rebus resoluta sunt.
Praeterea comparata cum immunotherapye productorum ab aegris qui iam plures chemotherapy lineas acceperant, apicem cellae CAR T sanguine insunt, necnon mediana car T cellae expansionis in hoc experimento altiores erant. prima acies CAR T Lorem cellulam.
"Haec T cellae congruentia cum maiore efficacia medicinali coniungi potuit, ex melioribus eventibus patientibus" Neelapu addidit.
Sequentes excellentes eventus interim ZUMA-12, investigatores instituunt ut aegros prosequantur, ut reactiones ad medicamen diuturnum sint.
“A randomised clinical trial would be required to definitely demonstrate that CAR T cell therapy is superior to existing standard of care with chemoimmunotherapy in these high-risk patients if the responses are persistent after prolonged follow-up,” Neelapu said. It also begs the question of whether CAR T cell treatment should be tested in intermediate-risk patients with big B-cell lymphoma.
